Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849796 | 1.00 | CCR2 (0.61) | CCR2CCR3HTR2CEPHX1 | |
| Acetic Acid SCHEMBL5702355 | 0.96 | CCR2 (0.57) | CCR2CCR3HTR2CEPHX1 | |
| Acetic Acid SCHEMBL5702362 | 0.96 | CCR2 (0.57) | CCR2CCR3HTR2CEPHX1 | |
| Nitric Acid SCHEMBL5268270 | 0.95 | CCR2 (0.57) | CCR2CCR3HTR2CEPHX1 | |
| Nitric Acid SCHEMBL5268257 | 0.95 | CCR2 (0.57) | CCR2CCR3HTR2CEPHX1 | |
| SCHEMBL4846680 | 0.85 | CCR2 (0.66) | CCR2CCR3 | |
| SCHEMBL4846664 | 0.85 | CCR2 (0.66) | CCR2CCR3 | |
| SCHEMBL4839283 | 0.82 | CCR2 (0.49) | CCR2CCR3HTR2CEPHX1 | |
| SCHEMBL5449234 | 0.82 | CCR2 (0.49) | CCR2CCR3HTR2CEPHX1 | |
| SCHEMBL27542093 | 0.78 | CCR2 (0.57) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100418951-C | Cycloamine derivative and its use as medicine | TEIJIN KASEI LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070249847-A1 | Method for Producing Acetamidopyrrolidine Derivatives and Intermediate Compounds Thereof | TEIJIN PHARMA LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249847-A1 | Method for Producing Acetamidopyrrolidine Derivatives and Intermediate Compounds Thereof | TEIJIN PHARMA LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249847-A1 | Method for Producing Acetamidopyrrolidine Derivatives and Intermediate Compounds Thereof | TEIJIN PHARMA LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1760075-A1 | METHOD FOR PRODUCING ACETAMIDOPYRROLIDINE DERIVATIVE AND INTERMEDIATE COMPOUND THEREOF | Teijin Pharma Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760075-A1 | METHOD FOR PRODUCING ACETAMIDOPYRROLIDINE DERIVATIVE AND INTERMEDIATE COMPOUND THEREOF | Teijin Pharma Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| CN-1240699-C | Therapeutic or prophylactic agent for chemokine-associated diseases | TEIJIN LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-1179341-B1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| CN-1660815-A | Cyclic amine derivatives and their use as drugs | TEIJIN LTD (JP) | 2005-08-31 | — | — | CN | disclosed |
| EP-1553085-A1 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1535909-A2 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1496981-A | Cyclic amine derivatives and their use as pharmaceuticals | ������������ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| CN-1384743-A | Remedies or preventives for diseases in association with chemokines | TEIJIN LTD (JP) | 2002-12-11 | — | — | CN | disclosed |
| US-6451842-B1 | Cyclic amine derivatives and their use as drugs | DUPONT PHARMACEUTICALS COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6410566-B1 | ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6362177-B1 | INHIBITION OF CHEMOKINE BINDING | TEIJIN LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1179341-A1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
| CN-1279668-A | Cyclic amine derivatives and their use as pharmaceuticals | TEIJIN LTD (JP) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249847-A1 | Method for Producing Acetamidopyrrolidine Derivatives and Intermediate Compounds Thereof | HDHD5, CBR3, ADH5 | CCR2 1243/4885CCR3 1225/4885HTR2C 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.